Cancer Detection & Prevention Programme

Detect risk early. Track biology precisely. Intervene before disease takes control.

A structured, physician-led clinical pathway designed to identify cancer risk early, detect molecular warning signs before symptomatic disease emerges, and guide proactive prevention with precision. Built around genomics, biomarker analysis, ctDNA surveillance, imaging, and longitudinal follow-up — cancer care transformed from reactive treatment to intelligent early detection.

Designed For

Adults 35+ seeking proactive cancer-risk prevention
Individuals with family history of breast, ovarian, colorectal, prostate, pancreatic, or related cancers
People concerned about inherited cancer predisposition or known pathogenic variants
Those with metabolic syndrome, chronic inflammation, or hormonal imbalance
Individuals with a prior cancer history needing structured preventive follow-up
Health-focused adults wanting more than routine annual checkup packages
Members who value an ongoing, physician-supervised programme over one-off testing

Diagnostics Included

Detailed medical, lifestyle, and risk-stratification consultation
Three-generation family history and hereditary cancer assessment
Germline genetic testing for key cancer-predisposition genes
Advanced blood panels for inflammation, metabolism, hormones, and infection-related risk
ctDNA and multi-cancer early detection blood testing (when clinically indicated)
Integrated molecular and clinical baseline for each member

Care Model

Physician interpretation of every test in the context of overall risk
Clear, protocol-driven pathways for early detection and risk reduction
Tailored recommendations on test cadence, recall intervals, and clinical reviews
Genetic counselling and structured family cascade testing where hereditary risk is found
Lifestyle, metabolic, and preventive strategies aligned to identified risk drivers
Defined escalation steps for indeterminate, abnormal, or clearly actionable results

Outcomes

Earlier recognition of inherited and acquired cancer risk
Greater chance of detecting molecular warning signals before symptoms appear
Improved stage-shift potential through timely escalation when needed
Reduced anxiety via clear, clinician-guided pathways instead of ad-hoc testing
More personalised prevention and surveillance than standard health checkups
A single, coherent programme instead of disconnected reports and opinions

The TLC Difference

TLC delivers molecularly informed, physician-led cancer prevention in a single, continuous programme — built for earlier action and long-term member confidence.

Price: On consultation